相关临床试验
61
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1963
进行中（未招募）
1
1.6%
已完成
35
57.4%
尚未招募
4
6.6%
招募中
11
18.0%
Unknown
9
14.8%
撤回
1
1.6%
暂无批准数据
- Astex Pharmaceuticals and Genentech have entered an exclusive worldwide research collaboration and license agreement to develop small molecule drug candidates for breast cancer. - The deal leverages Astex's fragment-based drug discovery platform to target a key cell-cycle-dependent regulator, with Genentech assuming responsibility for preclinical and clinical development as well as global commercialization. - Astex will receive a $25 million upfront payment and is eligible for milestone payments potentially exceeding $490 million, plus tiered royalties on net sales. - The drug discovery program originated from an earlier collaboration between Astex, Newcastle University, and Cancer Research Horizons, targeting an area of high unmet need in breast cancer therapy.
- A Newcastle University study found vitamin D insufficiency persisted year-round in older adults and minoritized ethnic groups in northern Britain, with no summer improvement. - More than half of adults aged 65 and older had insufficient vitamin D levels, with even higher rates among participants from minoritized ethnic backgrounds. - Researchers call for targeted public health strategies including clearer guidance, routine primary care assessments, and appropriate supplementation rather than relying on sunlight exposure. - The study, published in the European Journal of Clinical Nutrition, analyzed nearly 300 participants and was independently conducted despite funding from supplement manufacturer Better You Ltd.
- Surgeons at Rambam Eye Institute successfully transplanted the first fully 3D-printed corneal implant grown from cultured human cells, restoring sight to a legally blind patient. - The breakthrough technology allows a single donor cornea to be multiplied in the lab to create approximately 300 transparent implants using Precise Bio's regenerative platform. - This achievement could transform access to corneal transplants globally, particularly addressing donor shortages that prevent millions from receiving sight-saving care. - The procedure is part of an ongoing Phase 1 clinical trial assessing safety and tolerability in patients with corneal endothelial disease.
- Newcastle-based biotech InvenireX has secured £2 million in seed funding to commercialize its DNA nanotechnology platform that can detect diseases at the earliest biological stages. - The platform demonstrates 200-fold greater sensitivity than qPCR and 60-fold improvement over digital PCR, while reducing both time and cost per test by half. - The technology could enable detection of tumors as small as one millimeter up to a decade earlier than currently possible, with applications spanning cancer, HIV, and sepsis detection. - The funding round was led by DSW Ventures with participation from XTX Ventures, Cambridge Technology Capital, and experienced biotech angel investors.
- The EJS ACT-PD platform represents the first multi-arm, multi-stage clinical trial for Parkinson's disease in the UK, designed to test multiple treatments simultaneously against a shared placebo group. - The £26 million trial will initially recruit 1,600 participants to test telmisartan and terazosin, with ursodeoxycholic acid to be added in 2026, all repurposed drugs targeting different mechanisms of neurodegeneration. - The innovative platform design allows continuous testing of new therapies and facilitates progression from phase 2 to phase 3 trials without restarting the entire process. - Over 40 sites across the UK will offer virtual visits and home medication delivery to improve accessibility for participants with Parkinson's disease.
- Newcastle University researchers have developed iptacopan, the first therapy targeting the root cause of C3G kidney disease by preventing complement system damage to kidneys. - The Phase III APPEAR-C3G trial published in The Lancet demonstrated that iptacopan safely reduces protein loss and stabilizes kidney function compared to placebo. - This breakthrough offers hope for C3G patients who previously faced limited options beyond dialysis or kidney transplants, which often fail due to disease recurrence. - Novartis-developed iptacopan represents a paradigm shift from symptom management to addressing the underlying complement system abnormalities causing C3G.
- Newcastle University researchers demonstrated that 86% of atypical haemolytic uraemic syndrome (aHUS) patients can safely discontinue eculizumab after six months without disease relapse. - The study found early treatment withdrawal eliminates the 500-1,000 fold increased risk of meningococcal sepsis associated with lifelong eculizumab therapy. - Discontinuing eculizumab could save the NHS £4.2 million per patient over their lifetime, totaling £110.4 million over five years across the patient population. - The findings challenge previous recommendations for lifelong treatment and offer patients freedom from burdensome biweekly infusions and associated side effects.
- Eight healthy babies were born in Britain using an experimental technique that combines DNA from three people to prevent mothers from passing devastating mitochondrial diseases to their children. - Researchers from Newcastle University and Monash University performed the technique on fertilized embryos from 22 patients, with results published in the New England Journal of Medicine. - The method involves transferring genetic material from the mother's egg into a donor egg with healthy mitochondria, creating embryos free from mitochondrial diseases that can cause organ failure and death. - One baby showed slightly elevated abnormal mitochondria levels but remains below disease-causing thresholds, requiring ongoing monitoring as the child develops.
- Swedish researchers found that patients with specific genetic mutations who took 160mg aspirin daily after colorectal cancer surgery were 55% less likely to experience cancer recurrence over three years. - The Alascca trial involved over 3,500 patients, with 37% carrying PI3K pathway mutations that make them susceptible to aspirin's anti-cancer effects. - About 40% of colorectal cancer patients have these genetic mutations, suggesting a substantial population could benefit from this preventive treatment. - The findings emphasize the need for genetic testing of all colorectal cancers to identify patients who would benefit from aspirin therapy.
- Linear Diagnostics has received £1 million in NIHR funding to develop a rapid diagnostic test that can detect sexually transmitted infections in as little as five minutes using their Exponential Amplification technology. - The three-year project will focus on bacterial STIs including Neisseria gonorrhoeae and Chlamydia trachomatis, addressing the growing challenge of antibiotic-resistant strains that require rapid diagnosis and treatment. - The technology aims to overcome current diagnostic limitations by combining the speed of lateral flow tests with the accuracy of nucleic acid amplification tests, enabling same-day diagnosis and treatment within a single clinic visit.
